Q4 2025 Holdings
Filed 2026-02-17 | 38 holdings | $874.0M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Cullinan Therapeutics, Inc.(CGEM) | Common | 230031106 | $79.2M | 7,648,268 | 9.1% |
| Madrigal Pharmaceuticals Inc(MDGL) | Common | 558868105 | $56.4M | 96,780 | 6.4% |
| Liquidia Corp(LQDA) | Common | 53635D202 | $48.3M | 1,400,869 | 5.5% |
| Trevi Therapeutics Inc(TRVI) | Common | 89532M101 | $41.2M | 3,287,087 | 4.7% |
| Edgewise Therapeutics Inc(EWTX) | Common | 28036F105 | $41.1M | 1,655,256 | 4.7% |
| Revolution Medicines, Inc.(RVMD) | Common | 76155X100 | $40.3M | 505,672 | 4.6% |
| Agios Pharmaceuticals Inc(AGIO) | Common | 00847X104 | $35.5M | 1,303,373 | 4.1% |
| Uniqure NV(QURE) | Common | N90064101 | $33.1M | 1,381,628 | 3.8% |
| PTC Therapeutics Inc(PTCT) | Common | 69366J200 | $32.7M | 430,013 | 3.7% |
| Syndax Pharmaceuticals Inc(SNDX) | Common | 87164F105 | $28.1M | 1,337,702 | 3.2% |
| Dyne Therapeutics, Inc.(DYN) | Common | 26818M108 | $27.5M | 1,405,388 | 3.1% |
| Tarsus Pharmaceuticals Inc(TARS) | Common | 87650L103 | $26.9M | 328,869 | 3.1% |
| Stoke Therapeutics Inc(STOK) | Common | 86150R107 | $24.4M | 770,289 | 2.8% |
| Alumis Inc(ALMS) | Common | 022307102 | $23.4M | 2,401,992 | 2.7% |
| Urogen Pharma Ltd(URGN) | Common | M96088105 | $22.0M | 941,378 | 2.5% |
| Xenon Pharmaceuticals Inc(XENE) | Common | 98420N105 | $21.8M | 485,620 | 2.5% |
| Palvella Therapeutics Inc(PVLA) | Common | 697947109 | $21.5M | 205,745 | 2.5% |
| Natera Inc(NTRA) | Common | 632307104 | $21.4M | 93,551 | 2.5% |
| Corvus Pharmaceuticals Inc(CRVS) | Common | 221015100 | $21.1M | 2,743,671 | 2.4% |
| DBV Technologies S A(DBVT) | SPONSORED ADS | 23306J309 | $19.1M | 996,825 | 2.2% |
| Relay Therapeutics Inc.(RLAY) | Common | 75943R102 | $18.9M | 2,232,451 | 2.2% |
| Monte Rosa Therapeutics Inc(GLUE) | Common | 61225M102 | $18.4M | 1,173,376 | 2.1% |
| Bright Minds Biosciences Inc(DRUG) | Common | 10919W405 | $18.0M | 230,147 | 2.1% |
| Protagonist Therapeutics Inc(PTGX) | Common | 74366E102 | $17.4M | 199,471 | 2.0% |
| enGene Holdings, Inc.(ENGN) | Common | 29286M105 | $16.6M | 1,840,898 | 1.9% |
| Context Therapeutics Inc(CNTX) | Common | 21077P108 | $15.7M | 10,679,391 | 1.8% |
| Arcutis Biotherapeutics Inc(ARQT) | Common | 03969K108 | $15.4M | 531,200 | 1.8% |
| Ventyx Biosciences Inc(VTYX) | Common | 92332V107 | $14.8M | 1,639,061 | 1.7% |
| Oric Pharmaceuticals Inc(ORIC) | Common | 68622P109 | $14.7M | 1,798,717 | 1.7% |
| Belite Bio Inc(BLTE) | SPONSORED ADS | 07782B104 | $14.0M | 87,760 | 1.6% |
| Rapt Therapeutics Inc(RAPT) | Common | 75382E208 | $13.5M | 397,906 | 1.5% |
| Climb Bio Inc(CLYM) | Common | 28658R106 | $10.7M | 2,671,480 | 1.2% |
| Abivax SA(ABVX) | SPONSORED ADS | 00370M103 | $7.6M | 56,316 | 0.9% |
| Rocket Pharmaceuticals, Inc.(RCKT) | Common | 77313F106 | $5.6M | 1,586,076 | 0.6% |
| Maze Therapeutics Inc(MAZE) | Common | 578784100 | $3.4M | 81,145 | 0.4% |
| Evommune Inc(EVMN) | Common | 30054Y107 | $1.9M | 113,022 | 0.2% |
| Sarepta Therapeutics Inc(SRPT) | Common | 803607100 | $1.5M | 70,000 | 0.2% |
| Werewolf Therapeutics, Inc.(HOWL) | Common | 95075A107 | $883.5K | 1,393,557 | 0.1% |